Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Covington
Fish and Richardson
McKesson
Federal Trade Commission
QuintilesIMS
Boehringer Ingelheim
Colorcon
Daiichi Sankyo

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NITAZOXANIDE

« Back to Dashboard

Clinical Trials for Nitazoxanide

Trial ID Title Status Sponsor Phase Summary
NCT00001081 A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 To determine the frequency of complete, marked, and partial clinical responses in patients with cryptosporidiosis treated with 6 weeks of NTZ versus 21 days of placebo. To determine the safety of NTZ in subjects with cryptosporidiosis. There is no proven therapy for cryptosporidiosis in persons with AIDS. Nitazoxanide appears to be a good candidate drug for further evaluation because of its effectiveness in preclinical models, the data from early clinical trials and its safety profile. Cooperation between clinical researchers and basic scientists in clinical trials of agents for HIV infection and its complications is a high priority for the ACTG, the NIAID, and the NIH. Thus, it is important to design a clinical trial of NTZ that includes cooperation with basic scientists.
NCT00002158 A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis Unknown status Romark Laboratories L.C. N/A The purpose of this study is to see if nitazoxanide (NTZ) can be used to treat AIDS patients suffering from cryptosporidiosis (diarrhea caused by the parasite Cryptosporidium).
NCT00002444 A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea Completed Unimed Pharmaceuticals Phase 1 To determine the pharmacokinetics profile of single doses of nitazoxanide (NTZ) in patients with AIDS-related cryptosporidial diarrhea. To determine steady state concentrations of NTZ following repeated dosing. To assess the safety and efficacy of 4 dose levels of NTZ in these patients. Cryptosporidial enterocolitis in AIDS patients is frequently chronic and severe, contributing substantially to morbidity, mortality, and health care costs in this population. NTZ exhibits antimicrobial activity that may extend to Cryptosporidial infection.
NCT00004986 Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Terminated Romark Laboratories L.C. Phase 3 The purpose of this study is to see if it is safe and effective to treat cryptosporidiosis in AIDS patients with nitazoxanide.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nitazoxanide

Condition Name

Condition Name for Nitazoxanide
Intervention Trials
Chronic Hepatitis C 8
Influenza 5
HIV Infections 5
Cryptosporidiosis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nitazoxanide
Intervention Trials
Hepatitis C 13
Hepatitis 13
Hepatitis A 12
Hepatitis C, Chronic 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nitazoxanide

Trials by Country

Trials by Country for Nitazoxanide
Location Trials
United States 125
Egypt 14
Australia 10
Canada 3
New Zealand 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nitazoxanide
Location Trials
New York 11
Florida 10
California 8
Georgia 8
Texas 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nitazoxanide

Clinical Trial Phase

Clinical Trial Phase for Nitazoxanide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 12
Phase 2/Phase 3 7
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nitazoxanide
Clinical Trial Phase Trials
Completed 27
Recruiting 8
Not yet recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nitazoxanide

Sponsor Name

Sponsor Name for Nitazoxanide
Sponsor Trials
Romark Laboratories L.C. 22
National Institute of Allergy and Infectious Diseases (NIAID) 4
Tanta University 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nitazoxanide
Sponsor Trials
Other 36
Industry 26
NIH 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Colorcon
UBS
Citi
Fuji
QuintilesIMS
Daiichi Sankyo
Deloitte
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.